Triheptanoin improves brain energy metabolism in patients with Huntington disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 4, 2014
- Accepted in final form October 3, 2014
- First Published January 7, 2015.
Article Versions
- Previous version (January 7, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Isaac Mawusi Adanyeguh, MS,
- Daisy Rinaldi, PhD,
- Pierre-Gilles Henry, PhD,
- Samantha Caillet, MS,
- Romain Valabregue, PhD,
- Alexandra Durr, MD, PhD and
- Fanny Mochel, MD, PhD
- Isaac Mawusi Adanyeguh, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daisy Rinaldi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre-Gilles Henry, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Friedreich's Ataxia Research Alliance (2) Bob Allison Ataxia Research Center
NONE
NONE
NONE
NONE
NONE
NONE
- Samantha Caillet, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Valabregue, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alexandra Durr, MD, PhD and
(1) Pfizer - Genetic Services Advisory Board (2011)
NONE
NONE
(1) Journal of Huntington?s Disease (editor); (2) International Advisory Committee for Archives of Neurology (editor)
?Anaplerotic therapy of Huntington disease and other polyglutamine diseases?, BIO06353 Mochel/Durr (EP 06291873.5, 12/4/2006)
NONE
NONE
NONE
NONE
NONE
NONE
Pfizer Inc.
ANR (French Agency for Research) PHRC (Hospital Program for Clinical Research), grant BIOSCA (PI): 2010-2012
NONE
(1) Track HD study, Paris site investigator, 2008-2011 (2) Track On study, Paris site investigator, 2012-2015
NONE
NONE
?Anaplerotic therapy of Huntington disease and other polyglutamine diseases?, BIO06353 Mochel/Durr (EP 06291873.5, 12/4/2006)
NONE
NONE
NONE
- Fanny Mochel, MD, PhD
NONE
NONE
Funding for travel by Genzyme.
NONE
?Anaplerotic therapy of Huntington disease and other polyglutamine diseases?, BIO06353 Mochel/Durr (EP 06291873.5, 12/4/2006)
NONE
NONE
NONE
NONE
NONE
NONE
(1) Ipsen (2) Ultragenyx Pharmaceutical Inc
NONE
NONE
NONE
NONE
NONE
?Anaplerotic therapy of Huntington disease and other polyglutamine diseases?, BIO06353 Mochel/Durr (EP 06291873.5, 12/4/2006)
NONE
NONE
NONE
- From Inserm U 1127 (I.M.A., D.R., R.V., A.D., F.M.), CNRS UMR 7225, Sorbonne Universités, UPMC University Paris 06, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France; Center for Magnetic Resonance Research (P.-G.H.), University of Minnesota, Minneapolis; Departments of Dietetics (S.C.) and Genetics (A.D., F.M.), AP-HP, Pitié-Salpêtrière University Hospital, Paris; and Center for NeuroImaging Research (R.V.), Institut du Cerveau et de la Moelle épinière, Paris, France.
- Correspondence to Dr. Mochel: fanny.mochel{at}upmc.fr
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Clinical manifestations of intermediate allele carriers in Huntington diseaseEsther Cubo, María A. Ramos-Arroyo, Saul Martinez-Horta et al.Neurology, July 08, 2016 -
Null Hypothesis
Clinical manifestations of homozygote allele carriers in Huntington diseaseEsther Cubo, Saul-Indra Martinez-Horta, Frederic Sampedro Santalo et al.Neurology, March 13, 2019 -
Articles
Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington diseaseA. Sturrock, C. Laule, J. Decolongon et al.Neurology, November 08, 2010 -
Articles
Tetrabenazine as antichorea therapy in Huntington diseaseA randomized controlled trialHuntington Study Group et al.Neurology, February 13, 2006